MedTrace Logo

Molecularly Tailored Therapy for Pancreas Cancer

NCT01888978 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2018-04-09

No results posted yet for this study

Summary

Patient therapy is tailored according to the molecular profile of the patient's tumor.

Conditions

Interventions

DRUG

Gem-OX

DRUG

Gem-5FU

DRUG

Gem-Tax

DRUG

Modified FOLFOX-6

DRUG

Ox-Tax

DRUG

FOLFIRI

DRUG

Tax-Iri

Sponsors & Collaborators

  • Georgetown University

    lead OTHER

Principal Investigators

  • Michael Pishvaian, MD · Georgetown University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-12-31
Primary Completion
2016-06-30
Completion
2018-01-24

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01888978 on ClinicalTrials.gov